You are here: Industry Insights > Envigo

News List

LabCorp snaps up Envigo's nonclinical business fiercebiotech
April 28, 2019
LabCorp’s CRO business Covance will boost its nonclinical contract research services business as its parent company buys out the segment from Envigo, while the latter repositions.
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider pharmafocusasia
April 19, 2019
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
Envigo launches PATHWAY, an optimized safety assessment solution to enable first-in-human clinical trials pharmafocusasia
March 12, 2019
Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials.
Envigo merges with Avista, to be listed on Nasdaq fiercebiotech
August 25, 2017
Nonclinical service CRO Envigo is merging with Avista Healthcare Public Acquisition Corp., a deal that will value the combined company at $924 million.
Envigo launches R2G2 double knockout mouse model pharmaasia
April 07, 2017
Envigo announces that it will launch the “R2G2” mouse at the American Association for Cancer Research (AACR) annual meeting in Washington DC, April 1-5, 2017.
Envigo Launches R2G2 Research Model contractpharma
April 05, 2017
Envigo is launching the “R2G2” mouse, a Rag2/IL2RG double knockout model to help address common challenges researchers experience with current models used in oncology, immuno-oncology and infectious disease research.
Envigo’s fully validated highly sensitive method enables completion of thyroid hormone tests in acco pharmasia
March 22, 2017
Liquid chromatography-mass spectrometry technique can detect T3 and T4 levels in 4 and 13 day old F1 rats.
Envigo Expands R&D Capabilities contractpharma
March 16, 2017
To develop and validate five to seven ion channel In vitro tests for measuring cardiac risk potential